Text Size

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

This study is currently recruiting participants.
Verified April 2013 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00351611
First received: July 11, 2006
Last updated: April 29, 2013
Last verified: April 2013
History of Changes
  Purpose

Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.


Condition Intervention Phase
Epilepsies, Partial
 Drug: Lyrica (pregabalin)
Drug: placebo
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Randomized 12-Week Controlled Study Of Visual Field Change In Subjects With Partial Seizures Receiving Pregabalin Or Placebo

Resource links provided by NLM:

MedlinePlus related topics: Epilepsy Seizures
Drug Information available for: Pregabalin
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Changes in vision from baseline to end of study assessed by the Humphrey Visual Field Analzyer. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Visual acuity will be assessed at the baseline and end of the study. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Change in mean deviation score on the Humphrey Visual Field at baseline and end of the study. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 284
Study Start Date: July 2006
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active
Active drug
 Drug: Lyrica (pregabalin)
150 mg twice a day, oral administration
Placebo Comparator: Placebo
placebo comparator
 Drug: placebo
Twice a day, oral administration

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Epilepsy partial seizure subjects.
  • Currently taking 1 to 3 antiepileptic drugs.

Exclusion Criteria:

  • Pre-existing eye diseases (glaucoma).
  • Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00351611

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

  Show 114 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00351611     History of Changes
Other Study ID Numbers: A0081096
Study First Received: July 11, 2006
Last Updated: April 29, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
epilepsy partial seizure treatment with pregabalin or placebo
vision testing

Additional relevant MeSH terms:
Epilepsy
Epilepsies, Partial
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Pregabalin
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants

ClinicalTrials.gov processed this record on May 23, 2013